Final logistic regression model A (including SF-36 summary scores to base model) and model B (including HAQ to base model) for clinical remission at 6months for MTX-naive subjects at entry
| Predictors | log(OR) | SE of log(OR) | OR | 95% CI for OR | p-value |
| Final Model A (inclusion of SF-36 summary components to base model) | |||||
| Intercept* | – | – | – | – | – |
| Age at Entry, years | −0.0249 | 0.0076 | 0.98 | 0.96 to 0.99 | 0.0010 |
| Disease Duration, years | −0.0033 | 0.0300 | 1.00 | 0.94 to 1.06 | 0.9125 |
| Gender Male v Female | 0.9793 | 0.1953 | 2.66 | 1.82 to 3.90 | <0.0001 |
| Ethnicity White v Rest | 1.3489 | 0.4957 | 3.85 | 1.46 to 10.2 | 0.0065 |
| DAS28-ESR at Baseline | −0.3616 | 0.0891 | 0.70 | 0.58 to 0.83 | <0.0001 |
| Rheumatoid Factor Positivity Yes v No | −0.1352 | 0.2016 | 0.87 | 0.59 to 1.30 | 0.5024 |
| Randomised to MTX at start* Yes v No | – | – | – | – | – |
| Randomised to or on csDMARD at start Yes v No | 0.1809 | 0.2726 | 1.20 | 0.70 to 2.04 | 0.5070 |
| Randomised to Glucocorticoids at start Yes v No | 1.3375 | 0.2926 | 3.81 | 2.15 to 6.76 | <0.0001 |
| On Background Glucocorticoids at start Yes v No | 0.2478 | 0.4857 | 1.28 | 0.49 to 3.32 | 0.6099 |
| SF-36 Physical Summary Score | 0.0423 | 0.0118 | 1.04 | 1.02 to 1.07 | 0.0003 |
| SF-36 Mental Summary Score | 0.0209 | 0.0076 | 1.02 | 1.01 to 1.04 | 0.0063 |
| Final Model B (Inclusion of HAQ to base model) | |||||
| Intercept* | – | – | – | – | – |
| Age at Entry, years | −0.0191 | 0.0075 | 0.98 | 0.97 to 1.00 | 0.0109 |
| Disease Duration, years | −0.0032 | 0.0299 | 1.00 | 0.94 to 1.06 | 0.9157 |
| Gender Male v Female | 0.8551 | 0.1945 | 2.35 | 1.61 to 3.44 | <0.0001 |
| Ethnicity White v Rest | 1.3756 | 0.4937 | 3.96 | 1.50 to 10.4 | 0.0053 |
| DAS28-ESR at Baseline | −0.3489 | 0.0904 | 0.71 | 0.59 to 0.84 | 0.0001 |
| Rheumatoid Factor Positivity Yes v No | −0.1352 | 0.2008 | 0.87 | 0.59 to 1.29 | 0.5009 |
| Randomised to MTX at start* Yes v No | – | – | – | – | – |
| Randomised or on csDMARD at start Yes v No | 0.1789 | 0.2714 | 1.20 | 0.70 to 2.04 | 0.5097 |
| Randomised to Glucocorticoids at start Yes v No | 1.3976 | 0.2920 | 4.05 | 2.28 to 7.17 | <0.0001 |
| On Background Glucocorticoids at start Yes v No | 0.3778 | 0.4829 | 1.46 | 0.57 to 3.76 | 0.4340 |
| HAQ | −0.6325 | 0.1616 | 0.53 | 0.39 to 0.73 | <0.0001 |
*Estimates and SE are not estimable. MTX usage during study has been adjusted for in models. Majority of MTX-naïve subjects at trial entry received MTX during study (93%).xMark as
csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS28, DiseaseActivity Score 28; ESR, erythrocyte sedimentation rate; HAQ, Health AssessmentQuestionnaire; MTX, methotrexate.